Why the study?
Does adjunctive prednisolone reduce mortality and improve clinical outcomes in HIV seropositive patients with effusive tuberculous pericarditis?
Population
58 HIV seropositive patients aged 18-55 years with effusive tuberculous pericarditis.
Comparison
Prednisolone for six weeks added to standard… vs Placebo for six weeks added to standard short…
Design
RCT, randomly assigned, Double blind
Follow-up
18 months
Authors
Loading...
Supports adjunctive prednisolone in HIV-positive effusive TB pericarditis; confirms mortality benefit in this population.
Does adjunctive prednisolone reduce mortality and improve clinical outcomes in HIV seropositive patients with effusive tuberculous pericarditis?
Adjunctive prednisolone significantly reduces mortality and accelerates clinical improvement in HIV-positive patients with effusive tuberculous pericarditis.
James Hakim (2000) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: